AMPK-mediated cardioprotection of atorvastatin relates to the reduction of apoptosis and activation of autophagy in infarcted rat hearts

American Journal of Translational Research

Volumn 8, Issue 10, 2016, Pages 4160-4171

  Li, Qing ^a   Dong, Qiu Ting ^a   Yang, Yue Jin ^a   Tian, Xia Qiu ^a   Jin, Chen ^a   Huang, Pei Sen ^a   Jiang, Lei Pei ^a   Chen, Gui Hao ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

AMPK; Apoptosis; Atorvastatin; Autophagy; mTOR; Myocardial infarction

Indexed keywords

ATORVASTATIN; COMPOUND C; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 6; LC3 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRANSTHORACIC ECHOCARDIOGRAPHY; TUNEL ASSAY; WESTERN BLOTTING;

EID: 84993953236     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Lucas A, Mialet-Perez J, Daviaud D, Parini A, Marber MS, Sicard P. Gadd45γ regulates cardiomyocyte death and post-myocardial infarction left ventricular remodelling. Cardiovasc Res 2015; 108: 254-267.
2. Nesselmann C, Ma N, Bieback K, Wagner W, Ho A, Konttinen YT, Zhang H, Hinescu ME, Steinhoff G. Mesenchymal stem cells and cardiac repair. J Cell Mol Med 2008; 12: 1795-1810.
3. Awada HK, Hwang MP, Wang Y. Towards comprehensive cardiac repair and regeneration after myocardial infarction: aspects to consider and proteins to deliver. Biomaterials 2016; 82: 94-112.
4. Santos-Gallego CG, Vahl TP, Goliasch G, Picatoste B, Arias T, Ishikawa K, Njerve IU, Sanz J, Narula J, Sengupta P, Hajjar RJ, Fuster V, Badimon JJ. The sphingosine 1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse post-infarction left ventricular remodeling in a porcine model of ischemia-reperfusion. Circulation 2016; 133: 954-966.
5. Yang B, Zhao H XB, Wang YB, Zhang J, Cao YK, Wu Q, Cao F. Influence of interleukin-1 beta gene polymorphisms on the risk of myocardial infarction and ischemic stroke at young age in vivo and in vitro. Int J Clin Exp Pathol 2015; 8: 13806-13813.
6. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol 2010; 22: 124-131.
7. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009; 16: 966-975.
8. Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, Levine B, Sadoshima J. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res 2007; 100: 914-922.
9. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 2004; 306: 990-995.
10. Mathew R, White E. Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr Opin Genet Dev 2011; 21: 113-119.
11. Przyklenk K, Dong Y, Undyala VV, Whittaker P. Autophagy as a therapeutic target for ischaemia/reperfusion injury? Concepts, controversies, and challenges. Cardiovasc Res 2012; 94: 197-205.
12. Yang YJ, Qian HY, Huang J, Li JJ, Gao RL, Dou KF, Yang GS, Willerson JT, Geng YJ. Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts. Arterioscler Thromb Vasc Biol 2009; 29: 2076-2082.
13. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-305.
14. Li N, Zhang Q, Qian H, Jin C, Yang Y, Gao R. Atorvastatin induces autophagy of mesenchymal stem cells under hypoxia and serum deprivation conditions by activating the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Chin Med J 2014; 6: 1046-1051.
15. Zhang Q, Yang YJ, Wang H, Dong QT, Wang TJ, Qian HY, Xu H. Autophagy activation: a novel mechanism of atorvastatin to protect mesenchymal stem cells from hypoxia and serum deprivation via AMP-activated protein kinase/mammalian target of rapamycin pathway. Stem Cells Dev 2012; 21: 1321-1332.
16. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol 2010; 22: 124-131.
17. Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, Levine B and Sadoshima J. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res 2007; 100: 914-922.
18. Dong Q, Yang Y, Song L, Qian H, Xu Z. Atorva-statin prevents mesenchymal stem cells from hypoxia and serum-free injury through activating AMP-activated protein kinase. Int J Cardiol 2011; 153: 311-316.
19. Muller-Ehmsen J. Rebuilding a damaged he-art: long-term survival of transplanted neonatal rat cardiomyocytes after myocardial infarction and effect on cardiac function. Circulation 2002; 105: 1720-1726.
20. Xu H, Yang YJ, Qian HY, Tang YD, Wang H, Zhang Q. Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts. Circ J 2011; 75: 1476-1485.
21. Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, Abbate A, Vrtovec B, Khan BV, Vetrovec GW. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol 2009; 104: 1708-1716.
22. McKenney JM. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review. Postgrad Med 2012; 124: 7-20.
23. Ye Y, Lin Y, Perez-Polo R, Huang MH, Hughes MG, McAdoo DJ, Manickavasagam S, Uretsky BF, Birnbaum Y. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination. Am J Physiol Heart Circ Physiol 2007; 293: H813-H818.
24. Bekkers SC, Yazdani SK, Virmani R, Waltenberger J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 2010; 55: 1649-1660.
25. Sumagin R, Lomakina E, Sarelius IH. Leuko-cyte-endothelial cell interactions are linked to vascular permeability via ICAM-1-mediated signaling. Am J Physiol Heart Circ Physiol 2008; 295: H969-H977.
26. Lehnen TE, Lehnen AM, Tavares AM, Bello-Klein A, Markoski MM, Machado UF, Schaan B. Atorvastatin administered before myocardial infarction in rats improves contractility irrespective of metabolic changes. Clin Exp Pharmacol Physiol 2014; 41: 986-994.
27. Zhong C, Zhou Y, Liu H. Nuclear factor κB and anesthetic preconditioning during myo-cardial ischemia-reperfusion. Anesthesiology 2004; 100: 540-546.
28. Yuan X, Deng Y, Guo X, Shang J, Zhu D, Liu H. Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: partly involvement of TLR-4/MYD88 pathway. Biochem Biophys Res Commun 2014; 446: 292-297.
29. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 2011; 4: 98-108.
30. Tanai E, Frantz S. Pathophysiology of heart failure. Compr Physiol 2015; 6: 187-214.
31. Kandalam V, Basu R, Moore L, Fan D, Wang X, Jaworski DM, Oudit GY, Kassiri Z. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation 2011; 124: 2094-2105.
32. An Z, Yang G, He YQ, Dong N, Ge LL, Li SM, Zhang WQ. Atorvastatin reduces myocardial fibrosis in a rat model with post-myocardial infarction heart failure by increasing the matrix metalloproteinase-2/tissue matrix metalloproteinase inhibitor-2 ratio. Chin Med J (Engl) 2013; 126: 2149-2156.
33. Li XD, Yang YJ, Cheng YT, Dou KF, Tian Y, Meng XM. Protein kinase A-mediated cardioprotection of Tongxinluo relates to the inhibition of myocardial inflammation, apoptosis, and edema in reperfused swine hearts. Chin Med J (Engl) 2013; 126: 1469-1479.
34. Cui H, Li X, Li N, Qi K, Li Q, Jin C, Zhang Q, Jiang L, Yang Y. Induction of autophagy by tongxinluo through the MEK/ERK pathway protects human cardiac microvascular endothelial cells from hypoxia/reoxygenation injury. J Cardiovasc Pharm 2014; 64: 180-190.
35. Zhang ZL, Fan Y, Liu ML. Ginsenoside Rg1 inhibits autophagy in H9c2 cardiomyocytes exposed to hypoxia/reoxygenation. Mol Cell Biochem 2012; 365: 243-250.
36. Carloni S, Buonocore G, Balduini W. Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury. Neurobiol Dis 2008; 32: 329-339.
37. Loos B, Genade S, Ellis B, Lochner A, Engelbrecht AM. At the core of survival: autophagy delays the onset of both apoptotic and necrotic cell death in a model of ischemic cell injury. Exp Cell Res 2011; 317: 1437-1453.
38. Huang J, Nakamura K, Ito Y, Uzuka T, Morikawa M, Hirai S, Tomihara K, Tanaka T, Masuta Y, Ishii K, Kato K, Hamada H. Bcl-xL gene transfer inhibits Bax translocation and prolongs cardiac cold preservation time in rats. Circulation 2005; 112: 76-83.
39. Shao BZ, Han BZ, Zeng YX, Su DF, Liu C. The roles of macrophage autophagy in atherosclerosis. Acta Pharmacol Sin 2016; 37: 150-156.
40. Oral O, Akkoc Y, Bayraktar O, Gozuacik D. Physiological and pathological significance of the molecular cross-talk between autophagy and apoptosis. Histol Histopathol 2016; 31: 479-98.
41. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8: 851-864.
42. Ding WX, Ni HM, Gao W, Hou YF, Melan MA, Chen X, Stolz DB, Shao ZM, Yin XM. Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J Biol Chem 2007; 282: 4702-4710.
43. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation, and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284.
44. Kamada R, Toguchi Y, Nomura T, Imagawa T, Sakaguchi K. Tetramer formation of tumor suppressor protein p53: structure, function, and applications. Biopolymers 2016; 106: 598-612.
45. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005; 102: 8204-8209.
46. Jia F, Wu C, Chen Z, Lu G. Atorvastatin inhibits homocysteine-induced endoplasmic reticulum stress through activation of AMP-activated protein kinase. Cardiovasc Ther 2012; 30: 317-325.
47. Song L, Yang YJ, Dong QT, Qian HY, Xu H, Meng XM, Tang Y. Atorvastatin protects swine bone marrow mesenchymal stem cells from apoptosis through AMPK, but not PI3K/Akt pathway. Zhonghua Xin Xue Guan Bing Za Zhi 2011; 39: 1033-1038.